ReviewJournal of fungi (Basel, Switzerland)2022
Mycetoma: Development of Diagnosis and Treatment.
Review in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global sociodemographic, clinical, and epidemiological profiling of patients with mycetoma: A systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Actinomycetoma Caused byDiagnostics (Basel, Switzerland) · 2026Article
- Environmental and structural risk factors for mycetoma in the White Nile State, Sudan: an ethnographic study.International journal for equity in health · 2026Article
- Integrated action for skin NTDs: Deconstructing transmission, addressing knowledge gaps, and championing one health strategies.Nature communications · 2026Review
- Article
- [Myelopathy secondary to thoracic actinomycetoma].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Surgical Management and Antifungal Therapy for Extensive Eumycetoma of the Right Foot: A Case Report from Resource Limited Settings.International medical case reports journal · 2026Article
- Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China.Tropical medicine and health · 2025Review
- Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin.International journal of molecular sciences · 2025Review
- Dermatologic fungal neglected tropical diseases-Part I. Epidemiology and clinical features.Journal of the American Academy of Dermatology · 2025Review
- A Longstanding Case of Black Grain Mycetoma in a Somalian Male Patient: A Case Report.Clinical case reports · 2025Article
- Epidemiology, risk factors, and awareness of mycetoma among residents in Eastern Sinnar locality, Sudan, 2021.Journal of global health · 2025Article
- Mycetoma Epidemiology and Clinical Findings in Mogadishu, Somalia.Journal of tropical medicine · 2025Article
- Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.International journal of molecular sciences · 2025Article
- A Rare Case of Actinomycetoma In Pregnancy: Effective Treatment with the Combination of Amoxicillin-Clavulanic Acid.International journal of women's health · 2025Article
- Superior Anticancer and Antifungal Activities of New Sulfanyl-Substituted Niclosamide Derivatives.Biomedicines · 2024Article
- Cutaneous Hyalohyphomycosis and Its Atypical Clinical Presentations in Immunosuppressed Patients.Life (Basel, Switzerland) · 2024Review
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- First report on mycetoma in Turkana County-North-western Kenya.PLoS neglected tropical diseases · 2023Article
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycetoma describes a heterogeneous group of cutaneous and subcutaneous infections caused by either fungi (eumycetomas) or bacteria (actinomycetomas). It is characterized by a triad of clinical symptoms: painless subcutaneous tumor-like swelling, multiple sinuses and fistulas, and discharged grains in pus. This predominantly affects the feet in more than 70% of patients. It is endemic in the "mycetoma belt" regions, including Africa, South America, and South Asia. Autochthonous mycetoma is rare in the United States of America (USA). We recently reported a Latin American immigrant with eumycetoma in the State of Maryland, USA. With millions of immigrants from endemic regions, the true number of mycetomas in the USA is most likely higher than currently recognized. With the aim to raise the awareness of clinicians about mycetoma, especially dermatologists and podiatrists, we update the development of the epidemiology, etiology, clinical presentations, pathogenesis, diagnosis, differential diagnosis, and treatment of mycetoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.